ORGANIZATION

• Generic Use Rate at 72.2% in April-June: JGA
  October 1, 2018

• October 2019 “Only Option” for Drug Price Revision Tied to Sales Tax Hike: New FPMAJ Chief
  September 25, 2018

• 19 Companies Join JPMA Task Force on Quality Evaluation of Nucleic Acid Therapeutics
  September 18, 2018

• Think Tank Led by Ex-Pfizer Japan Chief to Compile Proposal on “100-Year Life” by Year-End
  September 5, 2018

• Bayer Yakuhin Chief Prinz Named Vice Chairman of EFPIA Japan
  September 3, 2018

• Ex-Pfizer Japan Chief Umeda to Now Helm Advocacy Group
  August 29, 2018

• Over Half of Companies Control Supply of Off-Label Information: Ihoken Survey
  August 27, 2018

• Regulatory Science Society Says “No” to Off-Label Info Supply by Drug Reps Conditionally OK’ed in Draft MHLW GLs
  August 24, 2018

• Drug Wholesalers Post Virtually Flat Sales in FY2017: JPWA
  August 10, 2018

• Total No. of Sales Reps Shrinks for 4 Years in a Row at 62,433: Survey
  July 27, 2018

• Generic Use Rate at 74.1% in January-March: JGA
  July 4, 2018

• Yokokura Wins 4th Term to Lead Japan Medical Association
  June 25, 2018

• Expand Exemption Criteria in New Off-Patent Price Cut Rule: Japan Pharma Lobby
  June 19, 2018

• Japan Pharma Group Calls for Careful Approach on PMP Deduction for Comparator Drugs
  June 19, 2018

• Don’t Make Coverage Decision on CEA, Tweak Prices with Limited Scope: FPMAJ
  June 18, 2018

• Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group
  June 18, 2018

• FPMAJ Welcomes Chuikyo’s Openness to Views of Experts on CEA: Drug Pricing Committee Chair
  June 18, 2018

• Atsushi Kamide of Astellas Elected as New Chairman of FPMAJ’s Drug Pricing Committee
  June 18, 2018

• Hiroki Nakatani Named as New Board Chair for GHIT Fund
  June 8, 2018

• JPMA Proposes Creation of Disease Registry to Employ Medical Data
  June 5, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 38
• 39
• 40
• 41
• 42
• 43
• 44
• 45
• 46
• …
• Next ›
• 最終 »